KPTI Q3'26 Earnings: EPS estimate is (0.95) USD

What happened

Karyopharm Therapeutics Inc. (KPTI) is set to announce its Q3'26 results on October 29 at 8:00 AM ET. The revenue estimate is 33.54 million USD, and the anticipated EPS, or earnings per share, is (0.95) USD.

Confirmed

Global impact / market context

The estimate points to a narrower loss per share than prior quarters, which matters because a smaller loss means less cash burned. Revenue near the estimate would fall short of the year-earlier reported figure, showing pressure on sales.

Analyst inference

KPTI has recently missed EPS estimates, including a large negative surprise in a prior quarter, while revenue surprised positively in another. That mixed record means the upcoming report will show whether cost trends improve and whether revenue stabilizes.

Analyst inference

What to watch

1. Watch the October 29 announcement at 8:00 AM ET for actual revenue against the 33.54 million USD estimate and EPS against the (0.95) USD estimate. Confirmed
2. Compare reported revenue with the year-earlier reported figure and the most recent reported quarter to judge whether the sales decline is slowing or continuing. Proposed
3. Track whether another EPS miss repeats the pattern seen in prior quarters, since repeated misses could reduce investor confidence in future estimates. Analyst inference

Evidence

• Original source link unavailable